Macrocycle Therapeutics to Treat Life-threatening Diseases
DOI:
https://doi.org/10.2533/chimia.2021.508PMID:
34233814Keywords:
Antibiotic, Breast cancer, Cxcr4 inhibitor, Macrocycle, Protein epitope mimeticAbstract
Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.Downloads
Published
2021-06-30
Issue
Section
Scientific Articles
License
Copyright (c) 2021 Gokhan Batur, Philipp Ermert, Johann Zimmermann, Daniel Obrecht
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
[1]
Chimia 2021, 75, 508, DOI: 10.2533/chimia.2021.508.